Ascendis Pharma furnishes Q3 2025 results press release

Ascendis Pharma A/S filed a Form 6-K to provide investors with a press release reporting its financial results for the fiscal quarter ended September 30, 2025.

Accepted by SEC EDGAR 11/12/2025 - 04:05 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Ascendis Pharma A/S filed a Form 6-K to provide investors with a press release reporting its financial results for the fiscal quarter ended September 30, 2025. The press release is furnished as Exhibit 99.1 and is dated November 12, 2025.

The filing indicates that Ascendis Pharma prepares its annual reports under cover of Form 20-F and uses this Form 6-K to make its quarterly financial information available to the market.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Ascendis Pharma A/S (ASND) disclose in this Form 6-K?

Ascendis Pharma A/S uses this Form 6-K to furnish a press release reporting its financial results for the fiscal quarter ended September 30, 2025, giving investors access to updated quarterly performance information.

Which period’s results are covered in Ascendis Pharma’s November 2025 Form 6-K?

The Form 6-K covers financial results for Ascendis Pharma A/S for the fiscal quarter ended September 30, 2025, as described in the attached press release identified as Exhibit 99.1 to the report.

What exhibit is included with Ascendis Pharma’s November 2025 Form 6-K?

The Form 6-K includes Exhibit 99.1, which is a press release dated November 12, 2025, reporting the financial results of Ascendis Pharma A/S for the fiscal quarter ended September 30, 2025.

What annual report form does Ascendis Pharma A/S (ASND) use?

Ascendis Pharma A/S files its annual reports under cover of Form 20-F, consistent with its status as a foreign private issuer, while using Form 6-K for interim and current information like quarterly financial results.

Who signed Ascendis Pharma’s November 2025 Form 6-K filing?

The Form 6-K was signed on behalf of Ascendis Pharma A/S by Michael Wolff Jensen, who serves as Executive Vice President and Chief Legal Officer, indicating authorized corporate approval of the submitted report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO SECTION 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of November, 2025

Commission File Number: 001-36815

Ascendis Pharma A/S

(Exact Name of Registrant as Specified in Its Charter)

Tuborg Boulevard 12

DK-2900 Hellerup

Denmark

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒   Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ☐

Furnished as an exhibit to this Report on Form 6-K is a press release reporting the financial results of Ascendis Pharma A/S for the fiscal quarter ended September 30, 2025.

Exhibits

Exhibit No.		Description
99.1		Press Release dated November 12, 2025.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				Ascendis Pharma A/S
Date: November 12, 2025				By:		/s/ Michael Wolff Jensen
						Michael Wolff Jensen
						Executive Vice President, Chief Legal Officer